NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
FEMPATCH (estradiol) by Pfizer is characteristics. Approved for contraception, vasomotor symptoms, menopause. First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FEMPATCH (estradiol) is a transdermal extended-release film approved in 1996 that delivers estradiol, the principal intracellular human estrogen, to treat vasomotor symptoms of menopause and contraception. The drug works by binding to nuclear estrogen receptors in target tissues and modulating pituitary gonadotropin secretion through negative feedback to reduce elevated LH and FSH levels in postmenopausal women.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), expect defensive commercialization focused on retention rather than growth expansion.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (3)
Worked on FEMPATCH at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.